Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Bupivacaine HCl for Adductor Canal Block Analgesia in Total Knee Arthroplasty
ChiCTR2500109025Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in knee osteoarthritis (OA) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Total consumption of sufentanil 0–72h postoperatively. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2500109025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109025.